Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
NEW YORK, June 22, 2015 /PRNewswire/ -- REPORT HIGHLIGHTS
The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.
This report provides:
An overview of the global diabetes treatment market.
Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.
Drug sales earned according to therapeutic area as well as by geography.
Analysis of the market's dynamics, specifically major issues, and challenges.
Relevant intellectual property (IP) and patent analysis.
SCOPE OF REPORT
The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.
Read the full report: http://www.reportlinker.com/p02720122-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article